AARTIDRUGS:NSE-Aarti Drugs Limited (INR)

COMMON STOCK | Drug Manufacturers—Specialty & Generic | NSE

Last Closing Price

INR 499.65

Change

+12.35 (+2.53)%

Market Cap

INR 11.51B

Volume

0.02M

Average Target Price

N/A
Average Analyst Rating

N/A

Fundamental Analysis

Verdict

About

Aarti Drugs Limited, through its subsidiaries, engages in the pharmaceuticals business in India and internationally. It offers active pharmaceutical ingredients in various therapeutic categories, including anti-inflammatory, cardioprotectants, antidiarrhoeals, antifungals, antiarthritis/osteoporosis, antibiotics, antidiabetics, Alzheimer's treatment, sedatives, vitamins, and alcoholism treatment. The company also provides pharmaceutical intermediate products comprising tinidazole, celecoxib, ciprofloxacin, clopidogrel, diclofenac, ketoconazole, nimesulide, raloxifene, and zolpidem; and specialty chemical products, such as benzene sulphonamide, benzene sulphonic acid, benzene sulphonic acid methyl ester, benzene sulphonyl chloride, cipro Q acid, levofloxacin Q acid, methyl nicotinate, N-methyl methane sulphonamide, diphenyl sulphone, norofloxacin Q acid, ofloxacin Q acid, ortho para toluene sulphonamide, ortho/para toluene sulphonic acid methyl ester, para chloro benzene sulphonamide, para chloro benzene sulphonyl chloride, para toluene sulphonamide, para toluene sulphonic acid methyl ester, para toluene sulphonyl chloride, and sodium benezene sulfinate. In addition, its products under development comprise Acamprosate for alcoholism; Dabigatran for use as an anticoagulant; Sevelamer for antihyperphosphatemia; Colsevelam for anti-cholestrol treatment; Drondarone and Olmesartan for the treatment of cardiovascular diseases; Valasartan for use as cardiprotectant; and Sitagliptin for use as an antidiabetic. Further, the company's pipeline product includes Mesalamine/Mesalazine and Loxoprofen Sodium for use as anti-inflammatory products; and Duloxetine for use as an antidepressant. Additionally, it offers contract manufacturing services. Aarti Drugs Limited was founded in 1984 and is based in Mumbai, India.

Technical Indicators

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2020-03-27 )

Largest Industry Peers for Drug Manufacturers—Specialty & Generic

Symbol Name Price(Change) Market Cap Price / Earning Ratio EV/EBITDA
DIVISLAB:NSE Divi's Laboratories Limited

-20.75 (-1.10%)

INR512.93B 40.06 27.77
DRREDDY:NSE Dr. Reddy's Laboratories Limit..

-32.05 (-1.09%)

INR454.36B 28.12 10.69
LUPIN:NSE Lupin Limited

-10.55 (-1.89%)

INR298.53B 102.46 11.45
CADILAHC:NSE Cadila Healthcare Limited

-4.15 (-1.62%)

INR277.54B 22.28 11.88
ALKEM:NSE Alkem Laboratories Limited

+37.85 (+1.64%)

INR274.18B 24.80 19.74
AUROPHARMA:NSE Aurobindo Pharma Limited

+30.85 (+8.54%)

INR194.77B 7.59 5.18
IPCALAB:NSE Ipca Laboratories Limited

-44.75 (-3.47%)

INR160.32B 25.82 17.52
AJANTPHARM:NSE Ajanta Pharma Limited

+62.00 (+5.27%)

INR108.14B 25.38 15.60
APLLTD:NSE Alembic Pharmaceuticals Limite..

+1.00 (+0.19%)

INR100.92B 13.77 11.17
NATCOPHARM:NSE NATCO Pharma Limited

+19.30 (+4.05%)

INR90.80B 18.69 13.17

ETFs Containing AARTIDRUGS

Symbol Name Weight Mer Price(Change) Market Cap

N/A

Market Performance

  Market Performance vs.
Industry/Classification (Drug Manufacturers—Specialty & Generic)
Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain -15.59% 55% F 86% B
Dividend Return N/A N/A N/A N/A N/A
Total Return -15.59% 55% F 86% B
Trailing 12 Months  
Capital Gain -22.91% 59% F 83% B
Dividend Return 0.15% 10% F 5% F
Total Return -22.76% 59% F 82% B-
Trailing 5 Years  
Capital Gain -19.35% 46% F 62% D-
Dividend Return 2.06% 36% F 19% F
Total Return -17.29% 46% F 60% D-
Average Annual (5 Year Horizon)  
Capital Gain -0.84% 43% F 38% F
Dividend Return 0.40% 43% F 33% F
Total Return -0.44% 41% F 38% F
Risk Return Profile  
Volatility (Standard Deviation) 15.68% 93% A 92% A-
Risk Adjusted Return -2.83% 41% F 36% F
Market Capitalization 11.51B 57% F 69% D+
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Key Financial Ratios

  Ratio vs. Industry/Classification
(Drug Manufacturers—Specialty & Generic)
Ratio vs. Market
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
Market Value  
Price / Earning Ratio 10.49 63% D 44% F
Price/Book Ratio 2.01 49% F 22% F
Price / Cash Flow Ratio 8.05 53% F 27% F
EV/EBITDA 6.40 59% F 43% F
Management Effectiveness  
Return on Equity N/A N/A N/A N/A N/A
Return on Invested Capital 16.82% 78% C+ 80% B-
Return on Assets N/A N/A N/A N/A N/A
Debt to Equity Ratio 38.31% 21% F 32% F
Technical Ratios  
Short Ratio N/A N/A N/A N/A N/A
Short Percent N/A N/A N/A N/A N/A
Beta 0.19 50% F 72% C-
Letter Grade Percentage Letter Grade Percentage Letter Grade Percentage
A+ 97%-100% A 93%-96% A- 90%-92%
B+ 97%-89% B 83%-86% B- 80%-82%
C+ 77%-79% C 73%-76% C- 70%-72%
D+ 67%-69% D 63%-66% D- 60%-62%
F 0%-59%

Annual Financials (INR)

Quarterly Financials (INR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

Fundamental Analysis Breakdown

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Poor risk adjusted returns

This company is delivering below median risk adjusted returns in its peers. Even if it is outperforming on returns , the returns are unpredictable. Proceed with caution.

Below median total returns

The company has under performed its peers on annual average total returns in the past 5 years.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Higly leveraged

The company is in the bottom half compared to its sector peers on debt to equity and is highly leveraged. However, do check the news and look at its sector and management statements. Sometimes this is high because the company is trying to grow aggressively.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector